BCL2 and small cell lung carcinoma: With awareness of Bcl-2 family targeted drugs entering early clinical trials, our feasibility experiment showed that Bcl-2 genetic abnormalities such as amplification, Bcl-2/IGH translocation, and triploidy can be detected in CTCs from SCLC patients (Figure 1E).